

# Contents

Acknowledgments .....	viii
Foreword .....	ix
Chapter 1: Introduction to Healthcare Product Labeling .....	1
Chapter 2: Content Development.....	5
Chapter 3: Core Labeling.....	11
Chapter 4: Target Labeling.....	23
Chapter 5: Pharmaceutical Labeling in the US.....	29
Chapter 6: Patient Labeling in the US.....	49
Chapter 7: EU Product Information .....	59
Chapter 8: Labeling of Human Drugs in Canada.....	69
Chapter 9: Labeling of Nonprescription Human Drugs in Canada .....	79
Chapter 10: Plain Language Labeling (PLL).....	87
Chapter 11: Operational Considerations Impact of Good Manufacturing Practices on Labeling, Container Labels and Carton Labeling (i.e., Printed Packaging Components) .....	91
Chapter 12: US Submissions and Launch Activities .....	111
Chapter 13: EU Submissions and Launch Activities.....	121
Chapter 14: Medical Device Labeling in the US .....	129
Chapter 15: EU Labeling for Medical Devices and In Vitro Diagnostic Medical Devices .....	137
Chapter 16: Canadian Labeling for Medical Devices and In Vitro Diagnostic Devices.....	143
 <b>Indexes</b>	
Laws, Regulations and Guidance Index .....	153
Subject Index .....	157

## **Figures**

Figure 2-1. VIOXX .....	9
Figure 3-1. Development of CCDS and Local Labeling Documents .....	17
Figure 5-1. Prescription Drug Labeling Sections 8.1–8.3 (Use in Specific Populations) .....	37
Figure 5-2. State Cannabis Programs .....	43
Figure 6-1. Drug Facts Label .....	54
Figure 11-1. NDC Number Example.....	93
Figure 11-2. Trade Bottle Label .....	99
Figure 11-3. Small Container Label (Small Label Exemption Rule) .....	99
Figure 11-4. Folding Carton for Pharmaceutical Drug Product .....	101
Figure 11-5. Biologic Label .....	105
Figure 11-6. Biologic Carton Label .....	106
Figure 12-1. Information Included in the SPL.....	114
Figure 12-2. Labeling Operations Activities in the Submission Process (black boxes).....	116
Figure 12-3. Submission Types and Implementation Timing for Postmarketing Labeling Changes.....	117
Figure 12-4. NDA/ANDA and BLA Annual Report Submission Timing .....	118
Figure 12-5. Labeling Summary Sections in NDA and BLA Annual Reports .....	119
Figure 13-1. Product Information Elements Included in Module 1 of the Common Technical Document (Administrative Information and Prescribing Information) in the EU .....	122
Figure 13-2. Timeline for New Applications and Extensions (Pre Opinion)—Mock-Up Review Points.....	125
Figure 14-1. Regulation 888.3040.....	131

## **Glossary**

Core Labeling.....	22
--------------------	----

## **Tables**

Table 1-1. Examples of Labeling Documents.....	2
Table 3-1. Distinctions Between Core Labeling and Regional and Local Data Sheets .....	13
Table 3-2. Content of the CCDS .....	13
Table 3-3. Sample Structure of CCDS.....	15
Table 3-4. Sample Mechanisms to Distinguish Optional Text Within a CCDS .....	15
Table 3-5. Distribution Package .....	16

Table 3-6. Sample Justification for Discrepancy Between Local Labeling and CCDS.....	18
Table 3-7. Elements to be Specified in Procedures Governing the Maintenance and Implementation of Core Labeling....	18
Table 3-8. Reference Product Information Used for Expedited and Periodic Safety Reporting.....	19
Table 4-1. Distinction Between Target Profiles and Target Labeling Documents.....	24
Table 4-2. Milestones in the Evolution of Target Labeling as a Drug Development Tool .....	24
Table 4-3. FDA’s Target Product Profile—Indications and Usage Section .....	26
Table 4-4. Target Labeling, Sample Tabular Structure for General Use.....	26
Table 5-1. Laws and Amendments Relating to Pharmaceutical Labeling in the US.....	30
Table 5-2. Required Elements for Container Labels of Prescription Drugs and Biologics.....	32
Table 5-3. Required Sections of Prescribing Information for Drugs and Biologics in the US (PLR Format).....	35
Table 5-4. Some Reasons for Labeling Revision .....	38
Table 6-1. Action Plan Criteria for Defining Useful Information.....	50
Table 6-2. Patient-Oriented Prescription Drug Labeling.....	50
Table 6-3. Labeling Regulations for Nonprescription Medicines.....	55
Table 7-1. SmPC Content.....	61
Table 7-2. Package Leaflet Content .....	63
Table 7-3. Additional Templates, Guidelines, Procedures and Training Presentations.....	66
Table 7-4. Review Process (Centralised Procedure) .....	67
Table 8-1. Product Monograph Core Sections .....	76
Table 9-1. CDFT Sections .....	82
Table 11-1. Select Resources on Pictogram Use .....	97